EXEMPT
(Reprinted with amendments adopted on April 21, 2025)
FIRST REPRINT S.B. 354
SENATE BILL NO. 354–SENATORS STONE;
OHRENSCHALL AND SCHEIBLE
MARCH 13, 2025
____________
JOINT SPONSOR: ASSEMBLYMEMBER EDGEWORTH
____________
Referred to Committee on Commerce and Labor
SUMMARY—Revises provisions relating to health insurance
coverage of prescription drugs. (BDR 57-1041)
FISCAL NOTE: Effect on Local Government: May have Fiscal Impact.
Effect on the State: Yes.
~
EXPLANATION – Matter in bolded italics is new; matter between brackets [omitted material] is material to be omitted.
AN ACT relating to insurance; prohibiting certain health plans from
requiring step therapy before providing coverage for
certain prescription drugs for the prevention of human
immunodeficiency virus or the treatment of human
immunodeficiency virus or hepatitis C; and providing
other matters properly relating thereto.
Legislative Counsel’s Digest:
1 Existing law requires certain public and private health plans, including the
2 Public Employees’ Benefits Program, to cover: (1) drugs that prevent the
3 acquisition of human immunodeficiency virus or that treat human
4 immunodeficiency virus or hepatitis C; (2) related laboratory and diagnostic
5 procedures; and (3) certain other services to test for, prevent or treat human
6 immunodeficiency virus or hepatitis C. (NRS 287.04335, 689A.0437, 689B.0312,
7 689C.1671, 695A.1843, 695B.1924, 695C.050, 695C.1743, 695G.1705) Existing
8 law prohibits such health plans from implementing any medical management
9 techniques on the coverage of such drugs or services, except the use of step
10 therapy. (NRS 287.010, 287.04335, 689A.0437, 689B.0312, 689C.1671,
11 695A.1843, 695B.1924, 695C.050, 695C.1743, 695G.1705) Sections 1-7 of this
12 bill remove the exemption for step therapy for private health plans, thereby
13 prohibiting such health plans from requiring step therapy before providing coverage
14 for a drug that: (1) prevents the acquisition of human immunodeficiency virus; or
15 (2) treats human immunodeficiency virus or hepatitis C. Sections 6-8.5 of this bill
16 authorize the Public Employees’ Benefits Program and Medicaid managed care
-
*SB354_R1*

– 2 –
17 organizations to continue requiring the use of step therapy for coverage of such
18 drugs as a medical management technique.
THE PEOPLE OF THE STATE OF NEVADA, REPRESENTED IN
SENATE AND ASSEMBLY, DO ENACT AS FOLLOWS:
1 Section 1. NRS 689A.0437 is hereby amended to read as
2 follows:
3 689A.0437 1. An insurer that offers or issues a policy of
4 health insurance shall include in the policy coverage for:
5 (a) All drugs approved by the United States Food and Drug
6 Administration for preventing the acquisition of human
7 immunodeficiency virus or treating human immunodeficiency virus
8 or hepatitis C in the form recommended by the prescribing
9 practitioner, regardless of whether the drug is included in the
10 formulary of the insurer;
11 (b) Laboratory testing that is necessary for therapy that uses a
12 drug to prevent the acquisition of human immunodeficiency virus;
13 (c) Any service to test for, prevent or treat human
14 immunodeficiency virus or hepatitis C provided by a provider of
15 primary care if the service is covered when provided by a specialist
16 and:
17 (1) The service is within the scope of practice of the provider
18 of primary care; or
19 (2) The provider of primary care is capable of providing the
20 service safely and effectively in consultation with a specialist and
21 the provider engages in such consultation; and
22 (d) The services described in NRS 639.28085, when provided
23 by a pharmacist who participates in the network plan of the insurer.
24 2. An insurer that offers or issues a policy of health insurance
25 shall reimburse:
26 (a) A pharmacist who participates in the network plan of the
27 insurer for the services described in NRS 639.28085 at a rate equal
28 to the rate of reimbursement provided to a physician, physician
29 assistant or advanced practice registered nurse for similar services.
30 (b) An advanced practice registered nurse or a physician
31 assistant who participates in the network plan of the insurer for any
32 service to test for, prevent or treat human immunodeficiency virus
33 or hepatitis C at a rate equal to the rate of reimbursement provided
34 to a physician for similar services.
35 3. An insurer shall not:
36 (a) Subject the benefits required by subsection 1 to medical
37 management techniques ; [, other than step therapy;]
-
*SB354_R1*

– 3 –
1 (b) Limit the covered amount of a drug described in paragraph
2 (a) of subsection 1;
3 (c) Refuse to cover a drug described in paragraph (a) of
4 subsection 1 because the drug is dispensed by a pharmacy through
5 mail order service; or
6 (d) Prohibit or restrict access to any service or drug to treat
7 human immunodeficiency virus or hepatitis C on the same day on
8 which the insured is diagnosed.
9 4. An insurer shall ensure that the benefits required by
10 subsection 1 are made available to an insured through a provider of
11 health care who participates in the network plan of the insurer.
12 5. A policy of health insurance subject to the provisions of this
13 chapter that is delivered, issued for delivery or renewed on or after
14 January 1, [2024,] 2027, has the legal effect of including the
15 coverage required by subsection 1, and any provision of the policy
16 that conflicts with the provisions of this section is void.
17 6. As used in this section:
18 (a) “Medical management technique” means a practice which is
19 used to control the cost or use of health care services or prescription
20 drugs. The term includes, without limitation, the use of step therapy,
21 prior authorization and categorizing drugs and devices based on
22 cost, type or method of administration.
23 (b) “Network plan” means a policy of health insurance offered
24 by an insurer under which the financing and delivery of medical
25 care, including items and services paid for as medical care, are
26 provided, in whole or in part, through a defined set of providers
27 under contract with the insurer. The term does not include an
28 arrangement for the financing of premiums.
29 (c) “Primary care” means the practice of family medicine,
30 pediatrics, internal medicine, obstetrics and gynecology and
31 midwifery.
32 (d) “Provider of health care” has the meaning ascribed to it in
33 NRS 629.031.
34 Sec. 2. NRS 689B.0312 is hereby amended to read as follows:
35 689B.0312 1. An insurer that offers or issues a policy of
36 group health insurance shall include in the policy coverage for:
37 (a) All drugs approved by the United States Food and Drug
38 Administration for preventing the acquisition of human
39 immunodeficiency virus or treating human immunodeficiency virus
40 or hepatitis C in the form recommended by the prescribing
41 practitioner, regardless of whether the drug is included in the
42 formulary of the insurer;
43 (b) Laboratory testing that is necessary for therapy that uses a
44 drug to prevent the acquisition of human immunodeficiency virus;
-
*SB354_R1*

– 4 –
1 (c) Any service to test for, prevent or treat human
2 immunodeficiency virus or hepatitis C provided by a provider of
3 primary care if the service is covered when provided by a specialist
4 and:
5 (1) The service is within the scope of practice of the provider
6 of primary care; or
7 (2) The provider of primary care is capable of providing the
8 service safely and effectively in consultation with a specialist and
9 the provider engages in such consultation; and
10 (d) The services described in NRS 639.28085, when provided
11 by a pharmacist who participates in the network plan of the insurer.
12 2. An insurer that offers or issues a policy of group health
13 insurance shall reimburse:
14 (a) A pharmacist who participates in the network plan of the
15 insurer for the services described in NRS 639.28085 at a rate equal
16 to the rate of reimbursement provided to a physician, physician
17 assistant or advanced practice registered nurse for similar services.
18 (b) An advanced practice registered nurse or a physician
19 assistant who participates in the network plan of the insurer for any
20 service to test for, prevent or treat human immunodeficiency virus
21 or hepatitis C at a rate equal to the rate of reimbursement provided
22 to a physician for similar services.
23 3. An insurer shall not:
24 (a) Subject the benefits required by subsection 1 to medical
25 management techniques ; [, other than step therapy;]
26 (b) Limit the covered amount of a drug described in paragraph
27 (a) of subsection 1;
28 (c) Refuse to cover a drug described in paragraph (a) of
29 subsection 1 because the drug is dispensed by a pharmacy through
30 mail order service; or
31 (d) Prohibit or restrict access to any service or drug to treat
32 human immunodeficiency virus or hepatitis C on the same day on
33 which the insured is diagnosed.
34 4. An insurer shall ensure that the benefits required by
35 subsection 1 are made available to an insured through a provider of
36 health care who participates in the network plan of the insurer.
37 5. A policy of group health insurance subject to the provisions
38 of this chapter that is delivered, issued for delivery or renewed on or
39 after January 1, [2024,] 2027, has the legal effect of including the
40 coverage required by subsection 1, and any provision of the policy
41 that conflicts with the provisions of this section is void.
42 6. As used in this section:
43 (a) “Medical management technique” means a practice which is
44 used to control the cost or use of health care services or prescription
45 drugs. The term includes, without limitation, the use of step therapy,
-
*SB354_R1*

– 5 –
1 prior authorization and categorizing drugs and devices based on
2 cost, type or method of administration.
3 (b) “Network plan” means a policy of group health insurance
4 offered by an insurer under which the financing and delivery of
5 medical care, including items and services paid for as medical care,
6 are provided, in whole or in part, through a defined set of providers
7 under contract with the insurer. The term does not include an
8 arrangement for the financing of premiums.
9 (c) “Primary care” means the practice of family medicine,
10 pediatrics, internal medicine, obstetrics and gynecology and
11 midwifery.
12 (d) “Provider of health care” has the meaning ascribed to it in
13 NRS 629.031.
14 Sec. 3. NRS 689C.1671 is hereby amended to read as follows:
15 689C.1671 1. A carrier that offers or issues a health benefit
16 plan shall include in the plan coverage for:
17 (a) All drugs approved by the United States Food and Drug
18 Administration for preventing the acquisition of human
19 immunodeficiency virus or treating human immunodeficiency virus
20 or hepatitis C in the form recommended by the prescribing
21 practitioner, regardless of whether the drug is included in the
22 formulary of the carrier;
23 (b) Laboratory testing that is necessary for therapy that uses a
24 drug to prevent the acquisition of human immunodeficiency virus;
25 (c) Any service to test for, prevent or treat human
26 immunodeficiency virus or hepatitis C provided by a provider of
27 primary care if the service is covered when provided by a specialist
28 and:
29 (1) The service is within the scope of practice of the provider
30 of primary care; or
31 (2) The provider of primary care is capable of providing the
32 service safely and effectively in consultation with a specialist and
33 the provider engages in such consultation; and
34 (d) The services described in NRS 639.28085, when provided
35 by a pharmacist who participates in the health benefit plan of the
36 carrier.
37 2. A carrier that offers or issues a health benefit plan shall
38 reimburse:
39 (a) A pharmacist who participates in the health benefit plan of
40 the carrier for the services described in NRS 639.28085 at a rate
41 equal to the rate of reimbursement provided to a physician,
42 physician assistant or advanced practice registered nurse for similar
43 services.
44 (b) An advanced practice registered nurse or a physician
45 assistant who participates in the network plan of the carrier for any
-
*SB354_R1*

– 6 –
1 service to test for, prevent or treat human immunodeficiency virus
2 or hepatitis C at a rate equal to the rate of reimbursement provided
3 to a physician for similar services.
4 3. A carrier shall not:
5 (a) Subject the benefits required by subsection 1 to medical
6 management techniques ; [, other than step therapy;]
7 (b) Limit the covered amount of a drug described in paragraph
8 (a) of subsection 1;
9 (c) Refuse to cover a drug described in paragraph (a) of
10 subsection 1 because the drug is dispensed by a pharmacy through
11 mail order service; or
12 (d) Prohibit or restrict access to any service or drug to treat
13 human immunodeficiency virus or hepatitis C on the same day on
14 which the insured is diagnosed.
15 4. A carrier shall ensure that the benefits required by
16 subsection 1 are made available to an insured through a provider of
17 health care who participates in the network plan of the carrier.
18 5. A health benefit plan subject to the provisions of this chapter
19 that is delivered, issued for delivery or renewed on or after
20 January 1, [2024,] 2027, has the legal effect of including the
21 coverage required by subsection 1, and any provision of the plan
22 that conflicts with the provisions of this section is void.
23 6. As used in this section:
24 (a) “Medical management technique” means a practice which is
25 used to control the cost or use of health care services or prescription
26 drugs. The term includes, without limitation, the use of step therapy,
27 prior authorization and categorizing drugs and devices based on
28 cost, type or method of administration.
29 (b) “Network plan” means a health benefit plan offered by a
30 carrier under which the financing and delivery of medical care,
31 including items and services paid for as medical care, are provided,
32 in whole or in part, through a defined set of providers under contract
33 with the carrier. The term does not include an arrangement for the
34 financing of premiums.
35 (c) “Primary care” means the practice of family medicine,
36 pediatrics, internal medicine, obstetrics and gynecology and
37 midwifery.
38 (d) “Provider of health care” has the meaning ascribed to it in
39 NRS 629.031.
40 Sec. 4. NRS 695A.1843 is hereby amended to read as follows:
41 695A.1843 1. A society that offers or issues a benefit
42 contract shall include in the benefit coverage for:
43 (a) All drugs approved by the United States Food and Drug
44 Administration for preventing the acquisition of human
45 immunodeficiency virus or treating human immunodeficiency virus
-
*SB354_R1*

– 7 –
1 or hepatitis C in the form recommended by the prescribing
2 practitioner, regardless of whether the drug is included in the
3 formulary of the society;
4 (b) Laboratory testing that is necessary for therapy that uses a
5 drug to prevent the acquisition of human immunodeficiency virus;
6 (c) Any service to test for, prevent or treat human
7 immunodeficiency virus or hepatitis C provided by a provider of
8 primary care if the service is covered when provided by a specialist
9 and:
10 (1) The service is within the scope of practice of the provider
11 of primary care; or
12 (2) The provider of primary care is capable of providing the
13 service safely and effectively in consultation with a specialist and
14 the provider engages in such consultation; and
15 (d) The services described in NRS 639.28085, when provided
16 by a pharmacist who participates in the network plan of the society.
17 2. A society that offers or issues a benefit contract shall
18 reimburse:
19 (a) A pharmacist who participates in the network plan of the
20 society for the services described in NRS 639.28085 at a rate equal
21 to the rate of reimbursement provided to a physician, physician
22 assistant or advanced practice registered nurse for similar services.
23 (b) An advanced practice registered nurse or a physician
24 assistant who participates in the network plan of the society for any
25 service to test for, prevent or treat human immunodeficiency virus
26 or hepatitis C at a rate equal to the rate of reimbursement provided
27 to a physician for similar services.
28 3. A society shall not:
29 (a) Subject the benefits required by subsection 1 to medical
30 management techniques ; [, other than step therapy;]
31 (b) Limit the covered amount of a drug described in paragraph
32 (a) of subsection 1;
33 (c) Refuse to cover a drug described in paragraph (a) of
34 subsection 1 because the drug is dispensed by a pharmacy through
35 mail order service; or
36 (d) Prohibit or restrict access to any service or drug to treat
37 human immunodeficiency virus or hepatitis C on the same day on
38 which the insured is diagnosed.
39 4. A society shall ensure that the benefits required by
40 subsection 1 are made available to an insured through a provider of
41 health care who participates in the network plan of the society.
42 5. A benefit contract subject to the provisions of this chapter
43 that is delivered, issued for delivery or renewed on or after
44 January 1, [2024,] 2027, has the legal effect of including the
-
*SB354_R1*

– 8 –
1 coverage required by subsection 1, and any provision of the plan
2 that conflicts with the provisions of this section is void.
3 6. As used in this section:
4 (a) “Medical management technique” means a practice which is
5 used to control the cost or use of health care services or prescription
6 drugs. The term includes, without limitation, the use of step therapy,
7 prior authorization and categorizing drugs and devices based on
8 cost, type or method of administration.
9 (b) “Network plan” means a benefit contract offered by a society
10 under which the financing and delivery of medical care, including
11 items and services paid for as medical care, are provided, in whole
12 or in part, through a defined set of providers under contract with the
13 society. The term does not include an arrangement for the financing
14 of premiums.
15 (c) “Primary care” means the practice of family medicine,
16 pediatrics, internal medicine, obstetrics and gynecology and
17 midwifery.
18 (d) “Provider of health care” has the meaning ascribed to it in
19 NRS 629.031.
20 Sec. 5. NRS 695B.1924 is hereby amended to read as follows:
21 695B.1924 1. A hospital or medical services corporation that
22 offers or issues a policy of health insurance shall include in the
23 policy coverage for:
24 (a) All drugs approved by the United States Food and Drug
25 Administration for preventing the acquisition of human
26 immunodeficiency virus or treating human immunodeficiency virus
27 or hepatitis C in the form recommended by the prescribing
28 practitioner, regardless of whether the drug is included in the
29 formulary of the hospital or medical services organization;
30 (b) Laboratory testing that is necessary for therapy using a drug
31 to prevent the acquisition of human immunodeficiency virus;
32 (c) Any service to test for, prevent or treat human
33 immunodeficiency virus or hepatitis C provided by a provider of
34 primary care if the service is covered when provided by a specialist
35 and:
36 (1) The service is within the scope of practice of the provider
37 of primary care; or
38 (2) The provider of primary care is capable of providing the
39 service safely and effectively in consultation with a specialist and
40 the provider engages in such consultation; and
41 (d) The services described in NRS 639.28085, when provided
42 by a pharmacist who participates in the network plan of the hospital
43 or medical services corporation.
44 2. A hospital or medical services corporation that offers or
45 issues a policy of health insurance shall reimburse:
-
*SB354_R1*

– 9 –
1 (a) A pharmacist who participates in the network plan of the
2 hospital or medical services corporation for the services described in
3 NRS 639.28085 at a rate equal to the rate of reimbursement
4 provided to a physician, physician assistant or advanced practice
5 registered nurse for similar services.
6 (b) An advanced practice registered nurse or a physician
7 assistant who participates in the network plan of the hospital or
8 medical services corporation for any service to test for, prevent or
9 treat human immunodeficiency virus or hepatitis C at a rate equal to
10 the rate of reimbursement provided to a physician for similar
11 services.
12 3. A hospital or medical services corporation shall not:
13 (a) Subject the benefits required by subsection 1 to medical
14 management techniques ; [, other than step therapy;]
15 (b) Limit the covered amount of a drug described in paragraph
16 (a) of subsection 1;
17 (c) Refuse to cover a drug described in paragraph (a) of
18 subsection 1 because the drug is dispensed by a pharmacy through
19 mail order service; or
20 (d) Prohibit or restrict access to any service or drug to treat
21 human immunodeficiency virus or hepatitis C on the same day on
22 which the insured is diagnosed.
23 4. A hospital or medical services corporation shall ensure that
24 the benefits required by subsection 1 are made available to an
25 insured through a provider of health care who participates in the
26 network plan of the hospital or medical services corporation.
27 5. A policy of health insurance subject to the provisions of this
28 chapter that is delivered, issued for delivery or renewed on or after
29 January 1, [2024,] 2027, has the legal effect of including the
30 coverage required by subsection 1, and any provision of the policy
31 that conflicts with the provisions of this section is void.
32 6. As used in this section:
33 (a) “Medical management technique” means a practice which is
34 used to control the cost or use of health care services or prescription
35 drugs. The term includes, without limitation, the use of step therapy,
36 prior authorization and categorizing drugs and devices based on
37 cost, type or method of administration.
38 (b) “Network plan” means a policy of health insurance offered
39 by a hospital or medical services corporation under which the
40 financing and delivery of medical care, including items and services
41 paid for as medical care, are provided, in whole or in part, through a
42 defined set of providers under contract with the hospital or medical
43 services corporation. The term does not include an arrangement for
44 the financing of premiums.
-
*SB354_R1*

– 10 –
1 (c) “Primary care” means the practice of family medicine,
2 pediatrics, internal medicine, obstetrics and gynecology and
3 midwifery.
4 (d) “Provider of health care” has the meaning ascribed to it in
5 NRS 629.031.
6 Sec. 6. NRS 695C.1743 is hereby amended to read as follows:
7 695C.1743 1. A health maintenance organization that offers
8 or issues a health care plan shall include in the plan coverage for:
9 (a) All drugs approved by the United States Food and Drug
10 Administration for preventing the acquisition of human
11 immunodeficiency virus or treating human immunodeficiency virus
12 or hepatitis C in the form recommended by the prescribing
13 practitioner, regardless of whether the drug is included in the
14 formulary of the health maintenance organization;
15 (b) Laboratory testing that is necessary for therapy that uses a
16 drug to prevent the acquisition of human immunodeficiency virus;
17 (c) Any service to test for, prevent or treat human
18 immunodeficiency virus or hepatitis C provided by a provider of
19 primary care if the service is covered when provided by a specialist
20 and:
21 (1) The service is within the scope of practice of the provider
22 of primary care; or
23 (2) The provider of primary care is capable of providing the
24 service safely and effectively in consultation with a specialist and
25 the provider engages in such consultation; and
26 (d) The services described in NRS 639.28085, when provided
27 by a pharmacist who participates in the network plan of the health
28 maintenance organization.
29 2. A health maintenance organization that offers or issues a
30 health care plan shall reimburse:
31 (a) A pharmacist who participates in the network plan of the
32 health maintenance organization for the services described in NRS
33 639.28085 at a rate equal to the rate of reimbursement provided to a
34 physician, physician assistant or advanced practice registered nurse
35 for similar services.
36 (b) An advanced practice registered nurse or a physician
37 assistant who participates in the network plan of the health
38 maintenance organization for any service to test for, prevent or treat
39 human immunodeficiency virus or hepatitis C at a rate equal to the
40 rate of reimbursement provided to a physician for similar services.
41 3. [A] Except as otherwise provided in subsection 4, a health
42 maintenance organization shall not:
43 (a) Subject the benefits required by subsection 1 to medical
44 management techniques ; [, other than step therapy;]
-
*SB354_R1*

– 11 –
1 (b) Limit the covered amount of a drug described in paragraph
2 (a) of subsection 1;
3 (c) Refuse to cover a drug described in paragraph (a) of
4 subsection 1 because the drug is dispensed by a pharmacy through
5 mail order service; or
6 (d) Prohibit or restrict access to any service or drug to treat
7 human immunodeficiency virus or hepatitis C on the same day on
8 which the enrollee is diagnosed.
9 4. A health maintenance organization that provides health
10 care services to members of the Public Employees’ Benefits
11 Program or recipients of Medicaid may subject the benefits
12 required by subsection 1 to step therapy.
13 5. A health maintenance organization shall ensure that the
14 benefits required by subsection 1 are made available to an enrollee
15 through a provider of health care who participates in the network
16 plan of the health maintenance organization.
17 [5.] 6. A health care plan subject to the provisions of this
18 chapter that is delivered, issued for delivery or renewed on or after
19 January 1, [2024,] 2027, has the legal effect of including the
20 coverage required by subsection 1, and any provision of the plan
21 that conflicts with the provisions of this section is void.
22 [6.] 7. As used in this section:
23 (a) “Medical management technique” means a practice which is
24 used to control the cost or use of health care services or prescription
25 drugs. The term includes, without limitation, the use of step therapy,
26 prior authorization and categorizing drugs and devices based on
27 cost, type or method of administration.
28 (b) “Network plan” means a health care plan offered by a health
29 maintenance organization under which the financing and delivery of
30 medical care, including items and services paid for as medical care,
31 are provided, in whole or in part, through a defined set of providers
32 under contract with the health maintenance organization. The term
33 does not include an arrangement for the financing of premiums.
34 (c) “Primary care” means the practice of family medicine,
35 pediatrics, internal medicine, obstetrics and gynecology and
36 midwifery.
37 (d) “Provider of health care” has the meaning ascribed to it in
38 NRS 629.031.
39 Sec. 7. NRS 695G.1705 is hereby amended to read as follows:
40 695G.1705 1. A managed care organization that offers or
41 issues a health care plan shall include in the plan coverage for:
42 (a) All drugs approved by the United States Food and Drug
43 Administration for preventing the acquisition of human
44 immunodeficiency virus or treating human immunodeficiency virus
45 or hepatitis C in the form recommended by the prescribing
-
*SB354_R1*

– 12 –
1 practitioner, regardless of whether the drug is included in the
2 formulary of the managed care organization;
3 (b) Laboratory testing that is necessary for therapy that uses a
4 drug to prevent the acquisition of human immunodeficiency virus;
5 (c) Any service to test for, prevent or treat human
6 immunodeficiency virus or hepatitis C provided by a provider of
7 primary care if the service is covered when provided by a specialist
8 and:
9 (1) The service is within the scope of practice of the provider
10 of primary care; or
11 (2) The provider of primary care is capable of providing the
12 service safely and effectively in consultation with a specialist and
13 the provider engages in such consultation; and
14 (d) The services described in NRS 639.28085, when provided
15 by a pharmacist who participates in the network plan of the
16 managed care organization.
17 2. A managed care organization that offers or issues a health
18 care plan shall reimburse:
19 (a) A pharmacist who participates in the network plan of the
20 managed care organization for the services described in NRS
21 639.28085 at a rate equal to the rate of reimbursement provided to a
22 physician, physician assistant or advanced practice registered nurse
23 for similar services.
24 (b) An advanced practice registered nurse or a physician
25 assistant who participates in the network plan of the managed care
26 organization for any service to test for, prevent or treat human
27 immunodeficiency virus or hepatitis C at a rate equal to the rate of
28 reimbursement provided to a physician for similar services.
29 3. A managed care organization shall not:
30 (a) Subject the benefits required by subsection 1 to medical
31 management techniques ; [, other than step therapy;]
32 (b) Limit the covered amount of a drug described in paragraph
33 (a) of subsection 1;
34 (c) Refuse to cover a drug described in paragraph (a) of
35 subsection 1 because the drug is dispensed by a pharmacy through
36 mail order service; or
37 (d) Prohibit or restrict access to any service or drug to treat
38 human immunodeficiency virus or hepatitis C on the same day on
39 which the insured is diagnosed.
40 4. A managed care organization that provides health care
41 services to members of the Public Employees’ Benefits Program or
42 recipients of Medicaid may subject the benefits required by
43 subsection 1 to step therapy.
44 5. A managed care organization shall ensure that the benefits
45 required by subsection 1 are made available to an insured through a
-
*SB354_R1*

– 13 –
1 provider of health care who participates in the network plan of the
2 managed care organization.
3 [5.] 6. A health care plan subject to the provisions of this
4 chapter that is delivered, issued for delivery or renewed on or after
5 January 1, [2024,] 2027, has the legal effect of including the
6 coverage required by subsection 1, and any provision of the plan
7 that conflicts with the provisions of this section is void.
8 [6.] 7. As used in this section:
9 (a) “Medical management technique” means a practice which is
10 used to control the cost or use of health care services or prescription
11 drugs. The term includes, without limitation, the use of step therapy,
12 prior authorization and categorizing drugs and devices based on
13 cost, type or method of administration.
14 (b) “Network plan” means a health care plan offered by a
15 managed care organization under which the financing and delivery
16 of medical care, including items and services paid for as medical
17 care, are provided, in whole or in part, through a defined set of
18 providers under contract with the managed care organization. The
19 term does not include an arrangement for the financing of
20 premiums.
21 (c) “Primary care” means the practice of family medicine,
22 pediatrics, internal medicine, obstetrics and gynecology and
23 midwifery.
24 (d) “Provider of health care” has the meaning ascribed to it in
25 NRS 629.031.
26 Sec. 8. (Deleted by amendment.)
27 Sec. 8.5. NRS 287.04335 is hereby amended to read as
28 follows:
29 287.04335 If the Board provides health insurance through a
30 plan of self-insurance, it shall comply with the provisions of NRS
31 439.581 to 439.597, inclusive, 686A.135, 687B.352, 687B.409,
32 687B.692, 687B.723, 687B.725, 687B.805, 689B.0353, 689B.255,
33 695C.1723, 695G.150, 695G.155, 695G.160, 695G.162,
34 695G.1635, 695G.164, 695G.1645, 695G.1665, 695G.167,
35 695G.1675, 695G.170 to 695G.1712, inclusive, 695G.1714 to
36 695G.174, inclusive, 695G.176, 695G.177, 695G.200 to 695G.230,
37 inclusive, 695G.241 to 695G.310, inclusive, 695G.405 and
38 695G.415, in the same manner as an insurer that is licensed pursuant
39 to title 57 of NRS is required to comply with those provisions [.] ,
40 except that the Board may subject the benefits required by NRS
41 695G.1705 to step therapy.
42 Sec. 9. (Deleted by amendment.)
43 Sec. 10. 1. This section becomes effective upon passage and
44 approval.
45 2. Sections 1 to 9, inclusive, of this act become effective:
-
*SB354_R1*

– 14 –
1 (a) Upon passage and approval for the purpose of adopting any
2 regulations and performing any other preparatory administrative
3 tasks that are necessary to carry out the provisions of this act; and
4 (b) On January 1, 2027, for all other purposes.
H
-
*SB354_R1*

[DELETED: E(FBN.3SS; I O E TES C1,2 S:AE PR S D p r t h i ( EE s t b p c f p d f t p o h v o t t o h v o h C a pE l r c p a h p i t E B P t c ( d t p t o h i v o t t h v o h C ( r l a d a ( c o s t t f p o t h p s h p f i a m m o t c o s d o s e t u o s ( 2 2 6 6 6 r t e f s t f p h p t]
[DELETED: –S 1  N 6 i h a t r a6  1  A i t o o i a p o( A d a b t U S F a D f p t a o h h C i t f r b t p r o w t d i i i t( L( A s t t f p o t h v o h C p b p o ( T ( T( T2  A( A p w p i t n p o t t r o r p t a p p( A a p r n o a p3  A( S t b r b s 1 t m]
[DELETED: –( L( R t c a d d i p ( o( P o r a t a s o d t t4  A i s e t t b r b5  A 1 [ 2 h t l e o i t6  A( “ a a c d a d b o( “ a i u w t a d o m i i a s p f a m c a w o t a d s o p c w t i T t d n i a( “ c m t p o f m i m o a g a( “S 2  N6  1  A i t o o i a p o( A d a b t U S F a D f p t a o h h C i t f r b t p r o w t d i i i t( L]
[DELETED: –( A s t t f p o t h v o h C p b p o ( T ( T( T2  A i t o o i a p o g h( A p w p i t n p o t t r o r p t a p p( A a p r n o a p3  A( S t b r b s 1 t m( L( R t c a d d i p ( o( P o r a t a s o d t t4  A i s e t t b r b5  A6  A( “]
[DELETED: – a a c d a d b o( “ p m a p o g h i b a i u w t f a d o c w t i T t d n i a( “ c m t p o f m i m o a g a( “S 3  N6  1  A( A d a b t U S F a D f p t a o h h C i t f r b t p r o w t d i i i t( L( A s t t f p o t h v o h C p b p o ( T ( T( T2  A c t o o i a h b p s( A t t r o r p t a p( A a p r n o a p]
[DELETED: –3  A( S t b r b s 1 t m( L( R t c a d d i p ( o( P o r a t a s o d t t4  A c s e t t b r b5  A i d i f d o r o o a 1 [ 2 h t l e o i t6  A( “ a a c d a d b o( “ p m a h b p o b a u w t f a d o m c( “ c m t p o f m i m o a g a( “S 4  N6  1  A s t o o i a b( A d a b t U S F a D f p t a o h]
[DELETED: – h C i t f r b t p r o w t d i i i t( L( A s t t f p o t h v o h C p b p o ( T ( T( T2  A s t o o i a b c s( A p w p i t n p o t t r o r p t a p p( A a p r n o a p3  A( S t b r b s 1 t m( L( R t c a d d i p ( o( P o r a t a s o d t t4  A s s e t t b r b5  A i d i f d o r o o a 1 [ 2 h t l e o i t]
[DELETED: –6  A( “ a a c d a d b o( “( “ c m t p o f m i m o a g a( “S 5  N6  1  A o i a p o h i s i i t( A d a b t U S F a D f p t a o h h C i t f r b t p r o w t d i i i t( L( A s t t f p o t h v o h C p b p o ( T ( T( T2  A h o m s c t o o]
[DELETED: –( A p w p i t n p o t 6 a a r e t t r o r t a p p a o a p( A a p r n o a p w p i t n p o t h o r o r p t a p f s3  A( S t b r b s 1 t m( L( R t c a d d i p ( o( P o r a t a s o d t t4  A b r b s 1 a m a t a a p o h c w p5  A 1 [ 2 h t l e o i t6  A( “ a a c d a d b o( “ a h o m s c u w t]
[DELETED: –( “ c m t p o f m i m o a g a( “S 6  N6  1  A( A d a b t U S F a D f p t a o h h C i t f r b t p r o w t d i i i t( L( A s t t f p o t h v o h C p b p o ( T ( T( T2  A h m o t o o i a( A p w p i t n p o t( A a p r n o a p w p i t n p o t h3  [( S t b r b s 1 t m]
[DELETED: –( L( R t c a d d i p ( o( P o r a t a s o d t t4  A h m o t p h s t m o t P E B o r o M m s t b5  A h m o s e t t[ 6  A h c p s t t p o t 1 [ 2 h t l e o i t[ 7  A( “ a a c d a d b o( “( “ c m t p o f m i m o a g a( “S 7  N6  1  A m c o t o o( A d a b t U S F a D f p t a o h h C i t f r b t p]
[DELETED: – r o w t d i i i t( L( A s t t f p o t h v o h C p b p o ( T ( T( T a p w p i t n p o t2  A( A p w p i t n p o t c o f t s d i N( A a p r n o a p f a s t t f p o t h3  A( S t b r b s 1 t m( L( R t c a d d i p ( o( P o r a t a s o d t t4  A m c o t p h c o M m s t b r b5  A]
[DELETED: –[ 6  A h c p s t t p o t 1 [ 2 h t l e o i t[ 7  A( “ a a c d a d b o( “ p m a h c p o b a a p i w o i p t a d s o d n i a a f t f o( “ c m t p o f m i m o a g a( “S 8  (S 8  N 2 i h a t r a2  I t B p h i t a t 4 i 6 6 6 6 6 6 6 6 6 6 6 6 t 6 i 6 t 6 t 6 i 6 aS 9  (S 1  1  T2  S]
[DELETED: –( U a p a o p a( O]